Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · Real-Time Price · USD
73.80
-0.70 (-0.94%)
At close: May 27, 2026, 4:00 PM EDT
71.45
-2.35 (-3.18%)
After-hours: May 27, 2026, 7:59 PM EDT
Sol-Gel Technologies Revenue
In the year 2025, Sol-Gel Technologies had annual revenue of $19.39M with 68.04% growth. Sol-Gel Technologies had revenue of $696.00K in the quarter ending December 31, 2025, a decrease of -93.96%.
Revenue (ttm)
$19.39M
Revenue Growth
-14.92%
P/S Ratio
12.43
Revenue / Employee
$692,429
Employees
28
Market Cap
241.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.39M | 7.85M | 68.04% |
| Dec 31, 2024 | 11.54M | 9.98M | 642.47% |
| Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
| Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
| Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
| Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
| Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
| Dec 31, 2018 | 129.00K | -45.00K | -25.86% |
| Dec 31, 2017 | 174.00K | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 75.11M |
| Compugen | 72.66M |
| Coherus Oncology | 46.88M |
| Orchestra BioMed Holdings | 32.72M |
| Foghorn Therapeutics | 28.22M |
| Alector | 18.42M |
| Adagene | 7.67M |
| Fate Therapeutics | 6.32M |
SLGL News
- 2 months ago - Sol-Gel Technologies 459K share Spot Secondary priced at $72.00 - TheFly
- 2 months ago - Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering - GlobeNewsWire
- 2 months ago - Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025 - GlobeNewsWire
- 2 months ago - Sol-Gel Technologies Annual report: Q4 2025 - Filings
- 2 months ago - Sol-Gel Technologies Slides: Corporate presentation - Filings
- 4 months ago - Sol-Gel Technologies price target raised to $110 from $50 at H.C. Wainwright - TheFly
- 5 months ago - Sol-Gel decides not to advance SGT-210 development in Darier disease - TheFly
- 6 months ago - Sol-Gel Technologies Earnings release: Q3 2025 - Filings